Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235790 | 0.85 | HTR2A (0.51) | HTR2ABCL9CTNNB1GAASMN1; SMN2 | |
| SCHEMBL23868084 | 0.84 | LMNA (0.41) | HTR2AGAAMAPTALDH1A1KMT2A | |
| SCHEMBL390309 | 0.82 | HTR2A (0.48) | HTR2ABCL9CTNNB1GAASMN1; SMN2 | |
| SCHEMBL27241497 | 0.81 | GAA (0.48) | HTR2ABCL9CTNNB1GAASMN1; SMN2 | |
| SCHEMBL5987375 | 0.81 | HTR2A (0.47) | HTR2ABCL9CTNNB1SMN1; SMN2POLB | |
| SCHEMBL14034486 | 0.80 | KMT2A (0.36) | HTR2AKMT2A | |
| SCHEMBL27900724 | 0.80 | GAA (0.48) | HTR2ABCL9CTNNB1GAASMN1; SMN2 | |
| SCHEMBL6396644 | 0.77 | HTR2A (0.65) | HTR2ABCL9CTNNB1GAASMN1; SMN2 | |
| SCHEMBL278663 | 0.77 | BCL9 (0.62) | HTR2ABCL9CTNNB1GAASMN1; SMN2 | |
| SCHEMBL9140032 | 0.76 | HTR2A (0.57) | HTR2ABCL9CTNNB1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865697-B2 | Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | claimed |
| EP-2268648-B1 | Crystalline (6R,7R)-7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1'-tert- butoxycarbonyl-2-oxo-[1,3]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2012-05-16 | — | — | EP | claimed |
| US-20110137026-A1 | Crystalline (6r,7r)-7--3- [(R)-1'-Tert-Butoxycarbonyl-2-Oxo-[1,3']Bipyrrolidinyl-(3e)-Ylidenemethyl]-8-Oxo-5-Thia-1-Aza-Bicyclo[4.2.0] Oct-2-Ene-2-Carboxylic Acid Benzhydryl Ester; Its Manufacture and Use | BASILEA PHARMACEUTICA AG (CH) | 2011-06-09 | — | — | US | claimed |
| EP-2268648-A1 | CRYSTALLINE (6R,7R)-7-{2-(5-AMINO-Ý1,2,4¨THIADIAZOL-3-YL)-2-Ý(Z)-TRITYLOXYIMINO¨-ACETYLAMINO}-3-Ý(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-Ý1,3'¨BIPYRROLIDINYL-(3E)-YLIDENEMETHYL¨-8-OXO-5-THIA-1-AZA-BICYCLOÝ4.2.0¨OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | Basilea Pharmaceutica AG (CH) | 2011-01-05 | — | — | EP | claimed |
| WO-2009127623-A1 | CRYSTALLINE (6R,7R)-7-{2-(5-AMINO-[1,2,4]THIADIAZOL-3-YL)-2-[(Z)-TRITYLOXYIMINO]-ACETYLAMINO}-3-[(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-[1,3']BIPYRROLIDINYL-(3E)-YLIDENEMETHYL]-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | BASILEA PHARMACEUTICA AG (CH) | 2009-10-22 | — | — | WO | claimed |
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | claimed |
| US-6649652-B2 | Hypotensive agents; hyperglycemic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-11-18 | — | — | US | claimed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | claimed |
| EP-1242059-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | claimed |
| WO-2001003685-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-01-18 | — | — | WO | claimed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4658663-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4637736-A1 | PRODRUGS OF DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-1999065920-A1 | DERIVATIVES OF 3-(2-OXO-[1,3']BIPYRROLIDINYL-3-YLIDENEMETHYL)-CEPHEMS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-23 | — | — | WO | disclosed |
| EP-0777479-A4 | DIOXOLENYLMETHYL CARBAMATES PROMOIETIES FOR AMINE DRUGS | MERCK & CO INC (US) | 1997-10-29 | — | — | EP | disclosed |
| EP-0777479-A1 | DIOXOLENYLMETHYL CARBAMATES PROMOIETIES FOR AMINE DRUGS | Merck & Co., Inc. (a New Jersey corp.) (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996002253-A1 | DIOXOLENYLMETHYL CARBAMATES PROMOIETIES FOR AMINE DRUGS | MERCK & CO., INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| US-5466811-A | Dioxolenylmethyl carbamates pro moieties for amine drugs | MERCK & CO., INC. (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | HTR2A 3588/4885BCL9 49/4885CTNNB1 770/4885 |
| US-20110137026-A1 | Crystalline (6r,7r)-7--3- [(R)-1'-Tert-Butoxycarbonyl-2-Oxo-[1,3']Bipyrrolidinyl-(3e)-Ylidenemethyl]-8-Oxo-5-Thia-1-Aza-Bicyclo[4.2.0] Oct-2-Ene-2-Carboxylic Acid Benzhydryl Ester; Its Manufacture and Use | MED1, MED16, CYP2D6 | HTR2A 1876/4885BCL9 727/4885CTNNB1 982/4885 |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | HTR2A 1877/4885BCL9 2630/4885CTNNB1 4432/4885 |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | HTR2A 1877/4885BCL9 2630/4885CTNNB1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.